Investigation of interaction between sodium-glucose cotransporter 2 inhibitors and FOLFOX with colorectal cancer and type 2 diabetes

Table 1 Comparison of baseline data between the two groups, mean ± SD

Indicators	Control group (n = 80)	Experimental group (n = 80)	t/χ2	P value
Age (years)	61.21 ± 8.49	60.75 ± 9.13	0.330	0.742
Gender (male/female)	45/35	47/33	0.102	0.749
Tumor location			0.120	0.989
Transverse colon	9	10
Right colon	25	24
Left colon	16	17
Sigmoid colon	30	29
TNM staging			0.332	0.847
III A	15	16
III B	46	48
III C	19	16
Glycated hemoglobin (%)	8.06 ± 0.84	8.02 ± 0.83	0.310	0.757
Fasting blood glucose (mmol/L)	7.81 ± 1.93	7.85 ± 1.89	-0.130	0.896
Epidermal growth factor receptor (ml/minute/1.73 m²)	87.92 ± 13.24	86.59 ± 14.52	0.605	0.546
Carcinoembryonic antigen	15.95 ± 3.53	16.83 ± 3.49	-1.587	0.115
Carbohydrate antigen 19-9	86.48 ± 3.99	87.35 ± 3.85	-1.405	0.162

It compares the continuous variables (e.g., age, glycated hemoglobin, fasting blood glucose, epidermal growth factor receptor, carcinoembryonic antigen, carbohydrate antigen 19-9) between the two groups by independent samples t-tests, and the categorical variables (e.g., gender, tumor location, TNM stage) by χ² test. The results show that there is no statistically significant difference between the two groups (P > 0.05).